Courtney Crim
- The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocolBy Jørgen Vestbo, Julie Anderson, Robert D. Brook, Peter M.A. Calverley, Bartolome R. Celli, Courtney Crim, Brett Haumann, Fernando J. Martinez, Julie Yates and David E. NewbyJørgen VestboJulie AndersonRobert D. BrookPeter M.A. CalverleyBartolome R. CelliCourtney CrimBrett HaumannFernando J. MartinezJulie Yates
- Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohortBy Alvar Agusti, Lisa D. Edwards, Bartolomé Celli, William MacNee, Peter M. A. Calverley, Hana Müllerova, David A. Lomas, Emiel Wouters, Per Bakke, Steve Rennard, Courtney Crim, Bruce E. Miller, Harvey O. Coxson, Julie C. Yates, Ruth Tal-Singer and Jørgen VestboAlvar Agusti1Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona and CIBER Enfermedades Respiratorias, FISIB, Mallorca, SpainLisa D. Edwards2GlaxoSmithKline, Research Triangle Park, NCBartolomé Celli3Dept of Respiratory Medicine; Brigham and Women's Hospital, Boston, MAWilliam MacNee4University of Edinburgh & Royal Infirmary, EdinburghPeter M. A. Calverley5Dept of Respiratory Medicine, University Hospital Aintree, LiverpoolHana Müllerova6Epidemiology, GlaxoSmithKline R&D, MiddlesexDavid A. Lomas7Dept of Medicine, University of Cambridge, Cambridge Institute for Medical Research, CambridgeEmiel Wouters8Dept of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The NetherlandsPer Bakke9Institute of Medicine, University of Bergen, Bergen10Dept of Thoracic Medicine, Haukeland University Hospital, Bergen, NorwaySteve Rennard11University of Nebraska Medical Center, Omaha, NECourtney Crim2GlaxoSmithKline, Research Triangle Park, NCBruce E. Miller12GlaxoSmithKline, King of Prussia, PA, USAHarvey O. Coxson13Dept of Radiology, University of British Columbia, Vancouver General Hospital, Vancouver, BC, CanadaJulie C. Yates2GlaxoSmithKline, Research Triangle Park, NCRuth Tal-Singer12GlaxoSmithKline, King of Prussia, PA, USAJørgen Vestbo14Dept of Respiratory Medicine, Odense University Hospital/University of Southern Denmark, Denmark15Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK
- A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPDBy Alvar Agustí, Luis de Teresa, Wilfried De Backer, Michael T. Zvarich, Nicholas Locantore, Neil Barnes, Jean Bourbeau and Courtney CrimAlvar Agustí1Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona2FISIB, CIBER Enfermedades Respiratorias (CIBERES), MallorcaLuis de Teresa3Medicina Innovadora, Clinica Mediterranea de Neurociencias, Alicante, SpainWilfried De Backer4University Hospital, University of Antwerp, Antwerp, BelgiumMichael T. Zvarich5GlaxoSmithKline, Research Triangle Park, NC, USANicholas Locantore5GlaxoSmithKline, Research Triangle Park, NC, USANeil Barnes6Respiratory Medicine, The London Chest Hospital, Barts Health NHS Trust, London, UKJean Bourbeau7Respiratory Epidemiology and Clinical Research Unit (RECRU), McGill University, Montreal, Quebec, CanadaCourtney Crim5GlaxoSmithKline, Research Triangle Park, NC, USA
- Clinical impact of anaemia in patients with chronic obstructive pulmonary disease: Results from ECLIPSE studyBy Mitja Lainscak, Lisa Edwards, Stefan Anker, Courtney Crim, Stephen Rennard, Emiel Wouters and William MacNeeMitja Lainscak1Division of Cardiology, University Clinic of Pulmonary and Allergic Diseases, Golnik, Slovenia2Applied Cachexia Research, Charite Universitaetsmedizin Berlin, Berlin, GermanyLisa Edwards3Respiratory CEDD Discovery Medicine, GlaxoSmithKline, Philadelphia, PA, United StatesStefan Anker2Applied Cachexia Research, Charite Universitaetsmedizin Berlin, Berlin, GermanyCourtney Crim3Respiratory CEDD Discovery Medicine, GlaxoSmithKline, Philadelphia, PA, United StatesStephen Rennard4Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, United StatesEmiel Wouters5Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, NetherlandsWilliam MacNee6MRC Centre for Inflammation Research, University of Edinburgh, United Kingdom
- Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbationsBy Peter M.A. Calverley, Mark T. Dransfield, Jean Bourbeau, Paul Jones, Nicola A. Hanania, Donald A. Mahler, Jørgen Vestbo, Andrew Wachtel, Fernando Martinez, Frank Barnhart, Lisa Sanford, Sally Lettis and Courtney CrimPeter M.A. Calverley1Clinical Science Centre, University Hospital Aintree, Liverpool, United KingdomMark T. Dransfield2Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, United StatesJean Bourbeau3Medicine, McGill University Health Centre, Montreal, CanadaPaul Jones4Division of Clinical Science, St. George's University, London, United KingdomNicola A. Hanania5Pulmonary and Critical Medicine, Baylor College of Medicine, Houston, United StatesDonald A. Mahler6Section of Pulmonary & Critical Care Medicine, Darmouth Medical School, Hanover, United StatesJørgen Vestbo7Respiratory Research Group, Manchester Academic Health Sciences Centre, Manchester, United KingdomAndrew Wachtel8UCLA School of Medicine, UCLA, Los Angeles, United StatesFernando Martinez9Department of Internal Medicine, University of Michigan, Ann Arbor, United StatesFrank Barnhart10Respiratory Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United StatesLisa Sanford11Quantitative Sciences Division, GlaxoSmithKline, Uxbridge, United KingdomSally Lettis11Quantitative Sciences Division, GlaxoSmithKline, Uxbridge, United KingdomCourtney Crim10Respiratory Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United States
- Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low-mid dose assessmentBy Edward M. Kerwin, Catherine Scott-Wilson, Lisa Sanford, Stephen I. Rennard, Alvar Agusti, Neil Barnes and Courtney CrimEdward M. Kerwin1Clinical Science Centre, Clinical Research Institute of Southern Oregon, Medford, United KingdomCatherine Scott-Wilson2Respiratory Medicines Development Centre, GlaxoSmithKline, Research Triangle Park, United StatesLisa Sanford3Quantitative Sciences Division, GlaxoSmithKline, Uxbridge, United KingdomStephen I. Rennard4Department of Internal Medicine, University of Nebraska Medical Center, Omaha, United StatesAlvar Agusti5Thorax Institute, Hospital Clinic, University of Barcelona, SpainNeil Barnes6Respiratory Medicine, Barts and the London NHS Trust, London, United KingdomCourtney Crim2Respiratory Medicines Development Centre, GlaxoSmithKline, Research Triangle Park, United States
- The minimal clinically important difference (MCID) for the six minute walk (6MW) test in COPD in relation to deathBy Michael Polkey, Martijn Spruit, Lisa Edwards, Michael Watkins, Vincent Pinto-Plata, Jørgen Vestbo, Peter Calverley, Ruth Tal-Singer, Alvar Agusti, Per Bakke, Harvey Coxson, David Lomas, William MacNee, Stephen Rennard, Edwin Silverman, Bruce Miller, Courtney Crim, Julie Yates, Emiel Wouters and Bartholeme CelliMichael Polkey1Consultant Physician, Royal Brompton Hospital, London, United KingdomMartijn Spruit2Program Development Centre, CIRO+, a Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsLisa Edwards3GSK, GlaxoSmithKline, Research Triangle Park,, NC, United StatesMichael Watkins3GSK, GlaxoSmithKline, Research Triangle Park,, NC, United StatesVincent Pinto-Plata4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United StatesJørgen Vestbo5Respiratory Medicine, University of Manchester, United KingdomPeter Calverley6Department of Respiratory Medicine, School of Clinical Science, University of Liverpool, United KingdomRuth Tal-Singer7Galaxy Initiative, GlaxoSmithKline, King of Prussia, PA, United StatesAlvar Agusti8Institut del Tòrax, Hospital Clínic, IDIBAPS, CIBER Enfermedades Respiratorias and Fundación Caubet-Cimera, Barcelona, SpainPer Bakke9Institute of Medicine, University of Bergen, NorwayHarvey Coxson10Department of Radiology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, CanadaDavid Lomas11Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, United KingdomWilliam MacNee12ELEGI Colt Research Labs, University of Edinburgh/MRC Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh, United KingdomStephen Rennard13Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of Nebraska Medical Center, Omaha, NE, United StatesEdwin Silverman14Channing Laboratory, Brigham & Women's Hospital, Boston, MA, United StatesBruce Miller7Galaxy Initiative, GlaxoSmithKline, King of Prussia, PA, United StatesCourtney Crim3GSK, GlaxoSmithKline, Research Triangle Park,, NC, United StatesJulie Yates3GSK, GlaxoSmithKline, Research Triangle Park,, NC, United StatesEmiel Wouters2Program Development Centre, CIRO+, a Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsBartholeme Celli4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
- Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPDBy Alvar Agusti, Wilfried De Backer, Luis de Teresa, Michael Zvarich, Nick Locantore, Neil Barnes, Jean Bourbeau and Courtney CrimAlvar Agusti1Thorax Institute, Hospital Clinic, University of Barcelona, SpainWilfried De Backer2Respiratory Medicine, University of Antwerp, Wilrijk, BelgiumLuis de Teresa3Internal Medicine, Clinica Mediterranea de Neurociencias, Alicante, SpainMichael Zvarich4Respiratory Medicine Development Center, GlaxoSmithKline Inc, Research Triangle Park, NC, United StatesNick Locantore4Respiratory Medicine Development Center, GlaxoSmithKline Inc, Research Triangle Park, NC, United StatesNeil Barnes5Respiratory Medicine, Barts and the London NHS Trust, London, United KingdomJean Bourbeau6Medicine, McGill University Health Centre, Montreal, QC, CanadaCourtney Crim4Respiratory Medicine Development Center, GlaxoSmithKline Inc, Research Triangle Park, NC, United States
- Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Mid-high dose assessmentBy Fernando Martinez, Joseph Boscia, Gregory Feldman, Catherine Scott-Wilson, Sally Kilbride, Leonardi Fabbri, Peter M.A. Calverley and Courtney CrimFernando Martinez1Department of Medicine, University of Michigan, Ann Arbor, United StatesJoseph Boscia2Clinical Research, CU Pharmaceutical Research, Union, United StatesGregory Feldman3Clinical Research, S. Carolina Pharmaceutical Research, Spartanburg, United StatesCatherine Scott-Wilson4Respiratory Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United KingdomSally Kilbride5Department of Oncology Haematology and Respiratory Diseases, University of Modena & Reggio Emilia, Modena, ItalyLeonardi Fabbri6Clinical Science Centre, University Hospital Aintree, Liverpool, United KingdomPeter M.A. Calverley6Clinical Science Centre, University Hospital Aintree, Liverpool, United KingdomCourtney Crim4Respiratory Medicine Development Center, GlaxoSmithKline, Research Triangle Park, United Kingdom
- A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPDBy Alvar Agustí, Luis de Teresa, Wilfried De Backer, Michael T. Zvarich, Nicholas Locantore, Neil Barnes, Jean Bourbeau and Courtney CrimArticle | Published in 2013 in European Respiratory JournalAlvar Agustí*Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain; and FISIB, CIBER Enfermedades Respiratorias (CIBERES), Mallorca, SpainLuis de Teresa¶Clinica Mediterranea de Neurociencias, Alicante, SpainWilfried De Backer#University of Antwerp, Antwerp, BelgiumMichael T. Zvarich+GlaxoSmithKline, Research Triangle Park, North Carolina, USANicholas Locantore+GlaxoSmithKline, Research Triangle Park, North Carolina, USANeil Barnes§Respiratory Medicine, The London Chest Hospital, Barts Health NHS Trust, London, UKJean BourbeaufMcGill University, Montreal, Quebec, CanadaCourtney Crim+GlaxoSmithKline, Research Triangle Park, North Carolina, USA
- The study to understand mortality and morbidity in COPD (SUMMIT) study protocolBy Jørgen Vestbo, Julie Anderson, Robert D Brook, Peter MA Calverley, Bartolome R Celli, Courtney Crim, Brett Haumann, Fernando Martinez, Julie Yates and David E NewbyArticle | Published in 2012 in European Respiratory JournalJørgen Vestbo*Dept of Respiratory Medicine J, Odense University Hospital and University of Southern Denmark, Odense, Denmark#Respiratory Research Group, Manchester Academic Health Sciences Centre, South Manchester University Hospital NHS Foundation Trust, Manchester, UKJulie Anderson¶Research & Development, GlaxoSmithKline, Stockley Park, Middlesex, UKRobert D Brook+University of Michigan Health System, Ann Arbor, Michigan, USAPeter MA Calverley§University of Liverpool, Dept of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UKBartolome R CellifPulmonary and Critical Care Division, Brigham and Females 's Hospital, Harvard Medical School, Boston, Massachusetts, USACourtney Crim**Research & Development, GlaxoSmithKline, Research Triangle Park, North Carolina, USABrett Haumann¶Research & Development, GlaxoSmithKline, Stockley Park, Middlesex, UKFernando Martinez##Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan, USAJulie Yates**Research & Development, GlaxoSmithKline, Research Triangle Park, North Carolina, USADavid E Newby¶¶Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
- Characteristics, stability and outcomes of the gold 2011 copd groups in the eclipse cohortBy Alvar Agusti, Lisa D. Edwards, Bartolomé Celli, William MacNee, Peter M. A. Calverley, Hana Mullerova, David A. Lomas, Emiel Wouters, Per Bakke, Steve Rennard, Courtney Crim, Bruce E. Miller, Harvey O. Coxson, Julie C. Yates, Ruth Tal-Singer, Jørgen Vestbo and for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators (see Appendix)Article | Published in 2013 in European Respiratory JournalAlvar Agusti*Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona and CIBER Enfermedades Respiratorias, FISIB, Mallorca, SpainLisa D. Edwards#GlaxoSmithKline, Research Triangle Park, NC, USABartolomé Celli¶Dept of Respiratory Medicine; Brigham and Women's Hospital, Boston, MA, USAWilliam MacNee+University of Edinburgh & Royal Infirmary, Edinburgh, UKPeter M. A. Calverley§Dept of Respiratory Medicine; University Hospital Aintree, Liverpool, UKHana MullerovafEpidemiology, GlaxoSmithKline R&D, Stockley Park, Middlesex, UKDavid A. Lomas**Dept of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UKEmiel Wouters##Dept of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, the NetherlandsPer Bakke¶¶Institute of Medicine, University of Bergen, and Dept of Thoracic Medicine, Haukeland University Hospital, Bergen, NorwaySteve Rennard++University of Nebraska Medical Center, Omaha, NE, USACourtney Crim#GlaxoSmithKline, Research Triangle Park, NC, USABruce E. Miller§§GlaxoSmithKline, King of Prussia, PA, USAHarvey O. CoxsonffDept of Radiology, University of British Columbia, Vancouver General Hospital, Vancouver, BC, CanadaJulie C. Yates#GlaxoSmithKline, Research Triangle Park, NC, USARuth Tal-Singer§§GlaxoSmithKline, King of Prussia, PA, USAJørgen Vestbo***Dept of Respiratory Medicine, Odense University Hospital/University of Southern Denmark, Denmark, and University of Manchester, Manchester Academic Health Sciences Centre, UK
- One-year change in health status and outcomes in chronic obstructive pulmonary diseaseBy Sarah Wilke, Paul Jones, Hana Müllerova, Nicholas Locantore, Jorgen Vestbo, Ruth Tal-Singer, Frits Franssen, Alvar Agusti, Per Bakke, Peter Calverley, Harvey Coxson, Courtney Crim, Lisa Edwards, David Lomas, William MacNee, Stephan Rennard, Julie Yates, Emiel Wouters and Martijn SpruitSarah Wilke1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsPaul Jones2Division of Clinical Science, St. George’s University of London, London, United KingdomHana Müllerova3Respiratory Epidemiology, GlaxoSmithKline, Uxbridge, United KingdomNicholas Locantore4GlaxoSmithKline, Research Triangle Park, North Carolina,Jorgen Vestbo5Department of Respiratory Medicine, Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark6Respiratory Research Group, Manchester Academic Health Sciences Centre, University Hospital South Manchester NHS Foundation, Manchester, United KingdomRuth Tal-Singer7GlaxoSmithKline, GlaxoSmithKline Research and Development, King of Prussia,Frits Franssen1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, NetherlandsAlvar Agusti8Thorax Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona and CIBER Enfermedades Respiratorias (CIBERES), Barcelona, SpainPer Bakke9Department of Thoracic Medicine, Institute of Clinical Science, University of Bergen, Haukeland University Hospital, Bergen, NorwayPeter Calverley10Division of Infection and Immunity Clinical Sciences Centre, University Hospital Aintree, Liverpool, United KingdomHarvey Coxson11Department of Radiology, Vancouver General Hospital, University of British Columbia, Vancover, CanadaCourtney Crim4GlaxoSmithKline, Research Triangle Park, North Carolina,Lisa Edwards4GlaxoSmithKline, Research Triangle Park, North Carolina,David Lomas12University of Cambridge, Cambridge Institute for Medical Research, Department of Medicine, Cambridge, United KingdomWilliam MacNee13MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United KingdomStephan Rennard14Department of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha,Julie Yates4GlaxoSmithKline, Research Triangle Park, North Carolina,Emiel Wouters1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, Netherlands15Department of Respiratory Medicine, Maastricht University Medical Centre+, Maastricht, NetherlandsMartijn Spruit1Department of Research & Education, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, Netherlands
- Continuous fat-free mass decline in COPD: fact or fiction?By Erica P.A. Rutten, Martijn A. Spruit, Merry-Lynn N. McDonald, Stephan Rennard, Alvar Agusti, Bartolome Celli, Bruce E. Miller, Courtney Crim, Peter M.A. Calverley, Corrine Hanson, William MacNee, Frits M.E. Franssen, Lowie Vanfleteren and Emiel F.M. WoutersArticle | Published in 2015 in European Respiratory JournalErica P.A. Rutten1Dept of Research and Education, CIRO, Horn, The Netherlands2Maastricht University Medical Center, Maastricht, The NetherlandsMartijn A. Spruit1Dept of Research and Education, CIRO, Horn, The Netherlands3REVAL – Rehabilitation Research Center, BIOMED – Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, BelgiumMerry-Lynn N. McDonald4Channing Division of Network Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USAStephan Rennard5Division of Internal Medicine, University of Nebraska, Nebraska Medical Center, Omaha, USAAlvar Agusti6Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain7CIBERES, Madrid, SpainBartolome Celli8Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USABruce E. Miller9GlaxoSmithKline, King of Prussia, PA, USACourtney Crim10GlaxoSmithKline, Research Triangle Park, NC, USAPeter M.A. Calverley11The University of Liverpool, Liverpool, UKCorrine Hanson12Medical Nutrition Education, University of Nebraska, Nebraska Medical Center, Omaha, USAWilliam MacNee13The University of Edinburgh, Edinburgh, UKFrits M.E. Franssen1Dept of Research and Education, CIRO, Horn, The NetherlandsLowie Vanfleteren1Dept of Research and Education, CIRO, Horn, The NetherlandsEmiel F.M. Wouters1Dept of Research and Education, CIRO, Horn, The Netherlands2Maastricht University Medical Center, Maastricht, The Netherlands
- Continuous fat-free mass decline in COPD: fact or fiction?By Erica P.A. Rutten, Martijn A. Spruit, Merry-Lynn N. McDonald, Stephen Rennard, Alvar Agusti, Bartolome Celli, Bruce E. Miller, Courtney Crim, Peter M.A. Calverley, Corrine Hanson, William MacNee, Frits M.E. Franssen, Lowie Vanfleteren and Emiel F.M. WoutersArticle | Published in 2015 in European Respiratory JournalErica P.A. Rutten1Dept of Research and Education, CIRO, Horn, The Netherlands2Maastricht University Medical Center, Maastricht, The NetherlandsMartijn A. Spruit1Dept of Research and Education, CIRO, Horn, The Netherlands3REVAL – Rehabilitation Research Center, BIOMED – Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, BelgiumMerry-Lynn N. McDonald4Channing Division of Network Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USAStephen Rennard5Division of Internal Medicine, University of Nebraska, Nebraska Medical Center, Omaha, USAAlvar Agusti6Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain7CIBERES, Madrid, SpainBartolome Celli8Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USABruce E. Miller9GlaxoSmithKline, King of Prussia, PA, USACourtney Crim10GlaxoSmithKline, Research Triangle Park, NC, USAPeter M.A. Calverley11The University of Liverpool, Liverpool, UKCorrine Hanson12Medical Nutrition Education, University of Nebraska, Nebraska Medical Center, Omaha, USAWilliam MacNee13The University of Edinburgh, Edinburgh, UKFrits M.E. Franssen1Dept of Research and Education, CIRO, Horn, The NetherlandsLowie Vanfleteren1Dept of Research and Education, CIRO, Horn, The NetherlandsEmiel F.M. Wouters1Dept of Research and Education, CIRO, Horn, The Netherlands2Maastricht University Medical Center, Maastricht, The Netherlands
- Continuous fat-free mass decline in COPD: fact or fiction?By Erica P.A. Rutten, Martijn A. Spruit, Merry-Lynn N. McDonald, Stephen Rennard, Alvar Agusti, Bartolome Celli, Bruce E. Miller, Courtney Crim, Peter M.A. Calverley, Corrine Hanson, William MacNee, Frits M.E. Franssen, Lowie Vanfleteren and Emiel F.M. WoutersErica P.A. Rutten1Dept of Research and Education, CIRO, Horn, The Netherlands2Maastricht University Medical Center, Maastricht, The NetherlandsMartijn A. Spruit1Dept of Research and Education, CIRO, Horn, The Netherlands3REVAL – Rehabilitation Research Center, BIOMED – Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, BelgiumMerry-Lynn N. McDonald4Channing Division of Network Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USAStephen Rennard5Division of Internal Medicine, University of Nebraska, Nebraska Medical Center, Omaha, NE, USAAlvar Agusti6Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain7CIBERES, Madrid, SpainBartolome Celli8Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USABruce E. Miller9GlaxoSmithKline, King of Prussia, PA, USACourtney Crim10GlaxoSmithKline, Research Triangle Park, NC, USAPeter M.A. Calverley11The University of Liverpool, Liverpool, UKCorrine Hanson12Medical Nutrition Education, University of Nebraska, Nebraska Medical Center, Omaha, NE, USAWilliam MacNee13The University of Edinburgh, Edinburgh, UKFrits M.E. Franssen1Dept of Research and Education, CIRO, Horn, The NetherlandsLowie Vanfleteren1Dept of Research and Education, CIRO, Horn, The NetherlandsEmiel F.M. Wouters1Dept of Research and Education, CIRO, Horn, The Netherlands2Maastricht University Medical Center, Maastricht, The Netherlands
- LATE-BREAKING ABSTRACT: Study to understand mortality and morbidIty in COPD (SUMMIT)By Jorgen Vestbo, Julie Anderson, Robert D. Brook, Peter Calverley, Bart Celli, Courtney Crim, Fernando Martinez, Julie Yates and David NewbyJorgen Vestbo1Centre for Respiratory Medicine and Allergy, The University of Manchester, Manchester, United KingdomJulie Anderson2Respiratory Statistics, GlaxoSmithKline, Uxbridge, Middlesex, United StatesRobert D. Brook3Division of Cardiovascular Medicine, Internal Medicine, University of Michigan, Ann Arbor, MI United StatesPeter Calverley4Respiratory Research Group, University Hospital Aintree, Liverpool, United KingdomBart Celli5Pulmonary and Critical Care Division, Brigham and Women's Hospital, Boston, MA United StatesCourtney Crim6Respiratory Research and Development, GlaxoSmithKline, Research Triangle Park, NC United StatesFernando Martinez7Division of Pulmonary and Critical Care Medicine, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY United StatesJulie Yates6Respiratory Research and Development, GlaxoSmithKline, Research Triangle Park, NC United StatesDavid Newby8United States and British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.